{"nctId":"NCT04070573","briefTitle":"Low Doses of Aspirin in the Prevention of Preeclampsia","startDateStruct":{"date":"2019-10-21","type":"ACTUAL"},"conditions":["Preeclampsia"],"count":400,"armGroups":[{"label":"81mg ASA","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: acetylsalicylic acid"]},{"label":"162mg ASA","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: acetylsalicylic acid"]}],"interventions":[{"name":"acetylsalicylic acid","otherNames":["aspirin","ASA"]}],"eligibilityModule":{"eligibilityCriteria":"Patients are currently only being enrolled at the New York Presbyterian Weill Cornell Medicine and at the New York Presbyterian Queens campuses.\n\nInclusion Criteria:\n\nPregnant patients, ≥18 years old, at less than 16 weeks' gestation (as documented by ultrasound) with at least one of the following risk factors for developing PE:\n\n* PE in a prior pregnancy\n* Chronic hypertension (prior to pregnancy or before 20 weeks' gestation)\n* Type 1 or 2 diabetes\n* Renal disease (proteinuria ≥300mg/day or estimated GFR\\<90mL/min/1.73 m2)\n* Multifetal gestation\n* Autoimmune disease (e.g. systemic lupus erythematous, antiphospholipid syndrome)\n\nExclusion Criteria:\n\n* Patient with known intention to terminate pregnancy\n* Major fetal malformation seen on ultrasound\n* Contraindication to ASA therapy (including but not limited to allergy and high bleeding risk)","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Preterm (<37 Weeks) Preeclampsia","description":"The incidence of preterm (\\<37 weeks) preeclampsia in high risk pregnant women treated with either 81 mg or 162 mg of daily aspirin during pregnancy.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Preeclampsia With Severe Features","description":"The incidence of preeclampsia with severe features (American College of Obstetricians and Gynecologists 2019 definition) in high-risk pregnant women treated with either 81 mg or 162 mg of daily aspirin during pregnancy.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"PRIMARY","title":"Composite Primary Outcome","description":"Composite of preterm preeclampsia and/or preeclampsia with severe features","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Aspirin Adherence","description":"Evaluate and compare the adherence of pregnant women to 81mg and 162mg of daily low-dose aspirin using a validated, Simplified Medication Adherence Questionnaire (SMAQ).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"122","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"126","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"101","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal and Fetal Outcomes","description":"Compare maternal and fetal outcomes in pregnant women at a high risk for preeclampsia who are treated with either 81mg or 162mg of daily aspirin during pregnancy, including gestational hypertension, postpartum hypertension, preterm delivery \\<37 weeks, fetal growth restriction (IUGR) or low birthweight (\\<2000g), placental abruption, ICU admission (maternal and neonatal), and maternal/fetal mortality.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Time-to-event for Preeclampsia: Gestational Age at Onset of Preeclampsia","description":"Compare the time-to-event for developing preeclampsia for women treated with 81mg vs 162mg of aspirin per day. The time to event analysis will be made using the gestational age at the onset of preeclampsia as a variable","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.1","spread":"5.08"},{"groupId":"OG001","value":"34.3","spread":"5.59"}]}]}]},{"type":"SECONDARY","title":"Aspirin Adherence- All Time Points Together","description":"To assess the adherence to low dose aspirin in pregnant women that are at high risk for preeclampsia and compare compliance rates for women on 81mg vs 162mg of aspirin per day using urine studies for salicylates and serum analysis. All time points together","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"337","spread":null},{"groupId":"OG001","value":"349","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Impact of Co-morbidities on Incidence of Preeclampsia","description":"Assess the impact of specific co-morbidities (diabetes, chronic hypertension, renal disease and autoimmune disease), blood pressure control, age and race on the relationship between treatment group (81mg vs 162mg aspirin per day) and preeclampsia incidence.","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":181},"commonTop":["Hypertension","Fetal concerns","Vaginal Spotting","COVID","Infection"]}}}